Robenacoxib vs. carprofen for the treatment of canine osteoarthritis; a randomized, noninferiority clinical trial

Reymond, N., Speranza, C., Gruet, P., Seewald, W., King, J. N. Robenacoxib vs. carprofen for the treatment of canine osteoarthritis; a randomized, noninferiority clinical trial. J. vet. Pharmacol. Therap. 35, 175–183. Robenacoxib is a member of the coxib class of nonsteroidal anti‐inflammatory drugs (NSAID), with high selectivity for the cyclooxygenase (COX)‐2 isoform of COX. In this study, the efficacy and tolerability of robenacoxib were compared with those of carprofen in canine osteoarthritis in a multi‐centre, prospective, randomized, blinded, positive‐controlled noninferiority clinical trial. Both drugs were administered orally once daily at recommended dosages: robenacoxib at 1–2 mg/kg (n = 125 dogs) and racemic carprofen at 2–4 mg/kg (n = 63 dogs) for a total of 12 weeks. The efficacy of the test compounds was assessed by veterinary investigators and owners using numerical rating scales at baseline and days 7, 14, 28, 56 and 84. In both groups, all scores were significantly (P